Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 258

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 258
---
, where DiamiR’s work is at an early stage.

DiamiR’s business objectives include the development of lab-developed
tests (LDTs) under Clinical Laboratory Improvement Amendments (CLIA) and FDA oversight guidelines primarily based on the identified miRNA
signatures, and potentially the development of blood protein biomarkers for risk stratification of cognitively unimpaired individuals
vs MCI vs AD patients. DiamiR believes the tests will be used to facilitate enrollment of better-defined patient groups into clinical
trials that are less heterogeneous than current practice affords, as well as for disease and treatment monitoring and screening. DiamiR
believes clinical tests for risk stratification are a valuable tool for personalized medicine, allowing healthcare providers to allocate
resources efficiently and deliver targeted interventions to those who are most likely to benefit.

The first test in the DiamiR’s pipeline,
CogniMIR, will be used to detect and determine risk of MCI, a heterogeneous condition characteristic of many NDs. Initially,
CogniMIR could be used by clinicians and researchers to screen patients for clinical studies aiming to prevent or to intervene
early in the development of neurodegeneration.

DiamiR aims to follow the development of CogniMIR
with the development and commercialization of tests for early, specific identification and monitoring of AD, PD, other NDs, Rett syndrome,
cancer, and potentially other diseases.

DiamiR’s Structure

DiamiR was incorporated in Delaware
on June 16, 2014 and is headquartered in Princeton, New Jersey. DiamiR operates through its wholly-owned operating subsidiary, DiamiR,
LLC (the “Subsidiary”) that was incorporated as a limited liability company in Delaware on September 17, 2009.

On October 1, 2014, DiamiR entered into a Share Exchange Agreement
with DiamiR, LLC, pursuant to which DiamiR acquired 100% of the issued and outstanding units of DiamiR, LLC in exchange for 4,282,000
shares (100%) of DiamiR’s common stock (the “Share Exchange”), and DiamiR, LLC became a wholly-owned subsidiary of DiamiR.
The Share Exchange is recognized as a combination of entities under common control as both DiamiR, LLC and DiamiR has been controlled
before and after the transaction by the same shareholders. As such, the financial statements and financial information contained in this